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ANALYSIS OF TWO MUTATIONS IN 
THE MTHFR GENE ASSOCIATED 
WITH MILD HYPERHOMOCYSTEIN-
AEMIA - HETEROGENEOUS 
DISTRIBUTION IN THE SOUTH 
AFRICAN POPULATION 
Charlotte L Scholtz, Hein J Odendaal, Rochelle Thiart, Lynzie 
Loubser, Renate Hillermann, Rhena Delport, W J Hayward 
Vermaak, Maritha J Kotze 
Objective, The frequencies of mutations 677C..-+T and 
1298A..-+C in the methylenetetrahydrofolate reductase 
(MTHFR) gene, previously shown to be associated with 
decreased enzyme activity that may lead to 
hyperhomocysteinaemia and consequently increased risk of 
cardiovascular disease (CVD), were determined in the 
South African population. 
Methods, Hinfi (677C..-+T) and MbolI (1298A..-+C) restriction 
enzyme analyses were performed on amplified DNA 
samples of 76 white, 73 coloured and 60 black subjects. 
Results, The mutant alleles of mutations 677C..-+T and 
1298A..-+C were more common in the white (allele 
frequencies 0.36 and 0.37, respectively) than in the black 
population (0.04 and 0.09), while intermediate frequencies 
were detected in the coloured population (0,18 and 0.30); 
Homozygosity for mutation 677C ..--+ T was not detected in 
the black cohort, while this genotype was detected in 1 
coloured (1.4%) and 8 white (105%) subjects, In the black 
population, 5% of the 60 subjects analysed were 
homozygous for mutation 1298A..-+C, compared with 
approximately 12% in both the white and coloured 
populations, 
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Conclusions. Since hyperhomocysteinaemia is a risk factor for 
premature CVD, the heterogeneous distribution of the 
677C~T and 1298A~C mutations across ethnic groups may 
partly explain ethnic differences in heart disease risk through 
decreased enzyme activity and hence increased homocysteine 
levels. 
S Afr Med f 2002; 92: 464-467. 
Cardiovascular disease (CVD) is a multifactorial condition 
caused by an interaction of genetic and environmental factors. 
In addition to well-known risk factors including low high-
density lipoprotein (HDL) and raised low-density lipoprotein 
(LDL) cholesterol, triglycerides, fibrinogen and lipoprotein(a) 
(Lp(a)), elevated plasma homocysteine concentration has 
consistently been identified as a risk factor for the development 
of CVD.1 In 1995 Frosst et al.' identified a C to T base change at 
nucleotide position 677 in the methylenetetrahydrofolate 
reductase (MTHFR) gene, which is responsible for increased 
thermolability of the enzyme, causing mild 
hyperhomocysteinaemia. Although various studies have 
demonstrated a positive association between CVD and this 
polymorphism, lack of association has also been reported, 
indicating that environmental interaction and the genetic 
background of the study population are important 
determinants of risk imposed by mutation 677C--+ T.3·5 More 
recently, a second common mutation, 1298A~C, resulting in 
decreased MTHFR activity, has been identified in the MTHFR 
gene.6 This sequence variant is not associated with elevated 
plasma homocysteine levels or a lower plasma folate 
concentration, although combined heterozygosity for both 
mutations results in increased thermolability of the enzyme 
and elevated homocysteine levels. Van der Put et al.' indicated 
that mutation 1298A-+C may be an additional risk factor for 
neural tube defects (NTDs), but its possible role in CVD has 
not yet been defined. 
Since the public health relevance of MTHFR mutations 
causing hyperhomocysteinaemia would largely depend on the 
frequency of disease-related mutations within a population, we 
analysed the 677C-+T and 1298A-+C MTHFR mutations in the 
South African population. We attempted to determine whether 
the distribution of MTHFR mutations among ethnic groups 
might be associated, at least in part, with ethnic differences in 
risk of CVD. The pattern of CVD differs in various population 
groups in South Africa/'' and this phenomenon has been 
attributed largely to differences in lifestyle and diet.'·' During 
recent years several studies have contributed to a growing 
awareness of the significant role of genetic factors predisposing 
an individual to different forms of heart disease, including the 
demonstration that three founder-related low-density 
lipoprotein receptor (LDLR) gene mutations are responsible for 
the high prevalence (1 /70) of familial hypercholesterolaemia 
(FH) in the South African Afrikaner population.10 These 
mutations shown to be responsible for the disease in 
approximately 90% of affected Afrikaners were absent in the 
black population, while detected in 10 - 20% of coloured FH 
patients.11 The detection of multiple founder-type LDLR gene 
mutations originating from European populations provided 
direct genetic evidence that Caucasoid admixture contributes 
significantly to the apparently high prevalence(> 1/500) of FH 
in the South African coloured population. This finding has 
demonstrated the potential consequences of recent admixture 
in populations with different disease risks, a phenomenon that 
may also be of relevance to the present study of MTHFR 
mutations in the general South African population. 
MATERIALS AND METHODS 
Subjects 
Blood samples of 209 individuals from three different ethnic 
groups in South Africa (Table I) were collected after obtaining 
informed consent: 60 Xhosa, Pedi and Zulu individuals (black 
population), 73 of mixed ancestry (coloured population) and 76 
Caucasians (white population). These included healthy blood 
donors, farm workers and laboratory personnel. In this study 
'white' or 'Afrikaner' refers to an individual of European 
descent, mainly Dutch, French, German and British origin; 
'coloured' refers to an individual of mixed ancestry, including 
Khoisan, African Negro, Madagascar, Javanese and European 
origin; and 'black' refers to South Africans of central African 
descent. 
Mutation detection 
Genomic DNA was extracted from whole blood according to 
the method of Miller et al.112 and amplified by the polymerase 
chain reaction (PCR) using previously described 
oligonucleotides.2•6 Amplified products were digested with 
HinfI and Mboll restriction enzymes for detection of mutations 
677C-+T and 1298A~C, respectively. Hinfi digested products 
were electrophoresed on a 12% polyacrylamide gel and Mboll 
digestions on a 20% polyacrylamide gel. Bands were visualised 
under ultraviolet light following ethidium bromide staining. 
Statistical analysis 
Chi-square values were calculated and their significance levels 
determined by two-way contingency tables. P-values of < 0.05 
were regarded as statistically significant. ll'.ill 
RESULTS AND DISCUSSION 
The frequencies of the 677C-+T and 1298A-+C MTHFR gene 
mutations were determined in the diverse South African 
population in order to evaluate their potential in predicting 
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Table I. Comparison of genotype distril;lution and allele frequencies of two MTHFR gene mutations in three ethnic groups in South Africa 
MTHFR Genotype/ 
mutations allele N 
677C..-+T cc 30 
CT 38 
TT 8 
Allele c 98 
Frequency T 54 
1298A..-+C AA 29 
AC 38 
cc 9 
Allele A 96 
Frequency c 56 
Genotype distributions and allele frequencies differed significantly: 
*White v. coloured: P < 0.03 (677 C...+ T mutation only). 
tcoloured v. Black: P < 0.004 (both mutations). 
+mack v. white: P < 0.0001 (both mutations). 
White* 












CVD risk in different ethnic groups. The results obtained 
following HinfJ.' and Mbon• restriction enzyme analysis in the 
unselected white, black and coloured populations are shown in 
Table I. Statistically significant differences for the two 
mutations were observed among the different South African 
population groups, with regard to both genotype distribution 
and allele frequencies (P < 0.01). However, no significant 
difference could be detected between whites and coloureds for 
mutation 1298A..-+C. The mutant alleles of mutations 677C..-+T 
and 1298A..-+C were more common in the white (allele 
frequencies 0.36 and 0.37, respectively) than in the black 
population (0.04 and 0.09), while intermediate frequencies were 
detected in the coloured population (0.18 and 0.30). 
Homozygosity for mutation 677C..-+T was not detected in black 
subjects, consistent with the findings of Ubbink et al.,13 who 
indicated that this genotype does not constitute a genetic risk 
factor for NTDs in South African blacks. These results are in 
accordance with the lower homocysteine levels reported 
previously in this population compared with Caucasians.1'·15 
Three of 60 black individuals analysed (5%) were homozygous 
for mutation 1298A..-+C. The frequency of the mutant allele of 
mutation 677C~T among whites and blacks was similar to 
those previously reported for the different ethnic groups.1' 
Mutation 1298A~C has not yet been studied extensively, but 
the frequency of the C-allele in South African Caucasians (0.37) 
was similar to that in control individuals (0.33) previously 
studied in the Netherlands.' 
The heterogeneous distribution of two MTHFR gene 
mutations among different ethnic groups in South Africa may 
be one of several factors underlying the differences observed in 
the risk of heart disease. This may particularly be the case for 
the extensively studied 677C~T mutation, which can be 
considered an established risk factor for CVD.2•3 The study 
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Coloured+ Blackt 
(N = 73) (N = 60) 
N % N % 
47 65 55 92 
25 34 5 8 
1 2 0 0 
119 82 113 96 
27 18 5 4 
40 55 52 87 
24 33 5 8 
9 12 3 5 
93 70 109 91 
39 30 11 9 
participants were recruited from the general South African 
population, where heart·attack deaths in the coloured 
population are less common than in the white population but 
more prevalent than in the black population.17 The intermediate 
frequency of the two common MTHFR mutations observed in 
the coloured population is in accordance with previous 
findings indicating an increased manifestation of coronary 
heart disease (CHD) in this population,18 possibly as a 
consequence of Caucasoid admixture.11 
While various studies have demonstrated that mild 
hyperhomocysteinaemia is associated with CHD, no conclusive 
reports have yet been published on its possible role in the 
development of CHD in FH patients. In a pilot study 
(performed in th,e Western Cape), a significant association was 
found between homozygosity for mutation 677C~T and CHD 
in patients with the common Afrikaner founder mutation 
D206E (P = 0.027), suggesting that the 677-TT genotype is 
associated with a high CHD risk in these FH patients.1' This 
findin$ could, however, not be replicated in an extended group 
of..j\frikaner FH heterozygotes from a different geographical 
region (Gauteng) in South Africa (M J Kotze, CL Scholtz, F J 
Raal - unpublished data). The contradictory findings in 
patients with similar genetic backgrounds may be suggestive of 
environmental differences such as vitamin intake, and/ or may 
reflect differences in selection criteria used at different lipid 
clinics. The allele frequency of mutation 1298A~C was not 
significantly higher in the CHD-positive group compared with 
the CHD-negative group, or with combined genotypes for both 
mutations (MJ Kotze, CL Scholtz and FJ Raal - unpublished 
results). The 677C~T mutation occurred at a significantly 
lower frequency (P < 0.05) in 102 molecularly characterised 
Afrikaner FH index cases (above the age of 25 years) compared 
with control individuals drawn from the same population, 
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which raises the possibility that the MTHFR gene represents a 
modifier locus for FH. 
It has also previously been noted that the effect of mutation 
677C---+T on homocysteine concentration may differ in separate 
studies as a result of a variable intake of folate, since this 
mutation leads to elevated plasma homocysteine 
concentrations only in individuals with a low folate status.20 
Biochemical analysis has indeed indicated higher folate levels 
in 20 FH heterozygotes (18.9 ± 19.4 nmol/l) (from the Afrikaner 
group where association between CHD and the MTHFR 
mutation could not be detected) compared with 20 controls 
(14.4 ± 6.2 nmol/l).21 The significantly lower plasma 
homocysteine concentrations detected in these FH patients may 
be related to a healthier lifestyle/diet in families known to be 
affected with FH. In light of recent reports on possible 
beneficial effects of vitamin supplementation in the prevention 
of CVD,22 dietary considerations should form an important 
aspect of future studies on the role of MTHFR mutations in 
CHD risk in FH. 
Although it may be too laborious and expensive to include 
dietary information and perform all the relevant biochemical 
tests for such a study, conclusive results would probably only 
be obtained in the absence of possible confounding factors. A 
recent study performed by Tonstad et al. 23 in children with FH 
addressed this issue. These authors convincingly demonstrated 
a moderately elevated plasma homocysteine level associated 
with a parental history of CVD, and demonstrated that 
homozygosity for mutation 677C---+T occurs more frequently in 
FH children with than in a group without a parental history of 
CVD. 
The wide spectrum of phenotypic variability observed in FH 
patients sharing the same defective allele24-26 suggests that other 
important predictors of CHD risk in FH remain to be 
identified. A population-based approach would only reveal 
major additive factors, since different CHD risk factors could 
be present in different FH families. The key to unravelling the 
various factors likely to be involved in the development of 
CHD in FH heterozygotes are probably, as suggested 
previously,24 to be found in families where the clinical 
expression of FH varies among relatives. 
In summary, we have demonstrated a heterogeneous 
distribution of MTHFR genotypes among different ethnic 
groups, which may partly explain differences14 in the risk for 
heart disease in the genetically distinct populations of South 
Africa. Although it is possible that deleterious MTHFR 
genotypes will only emerge as a risk factor for CVD in 
populations with a low folate status, it appears appropriate to 
screen all patients with a history of premature atherosclerosis 
for established risk factors, including elevated homocysteine 
levels, which can be normalised. Assessment of genetic risk 
factors in families with a history of CVD, and timely 
implementation of appropriate measures before the onset of 
disease, may represent an important strategy towards 
prevention of CVD predicted to become the leading cause of 
death in developing countries by the year 2020. 
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